Rapport Therapeutics expects cash to fund requirements through 2026

By Yahoo! Finance   |   2 years ago
Rapport Therapeutics expects cash to fund requirements through 2026

The Company's cash reserves decreased to $320.7 million in Q3 2024 from $336.1 million in Q2 2024 due to operating expenses. The current funds are sufficient to cover expenses and investments until the end of 2026.

Read More

Did you find this insightful?